Oncosil Medical Share Price and Company Fundamentals



Price
$0.083
Change
-0.003 (-3.488%)
52 week
0.083 - 0.18

Last traded: Today at 4:38 AM

OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. Its lead product is OncoSil, a brachytherapy device that implants a pre-determined dose of beta radiation directly into cancerous tissue for the treatment of cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.

Key Metrics

PE ratio

-

PB ratio

3.95

Dividend yield

Beta

0.15

Market cap

$67.01M

Enterprise value

$62.08M

Company profile

Primary activitiesOncology Research and Development
Industry / SectorMedical Devices / Healthcare
Websitehttp://www.oncosil.com.au
Mailing address15 Blue Street Suite 503 Level 5 North Sydney NSW 2060 Australia
Phone / Fax61 2 9223 3344 / 61 2 9252 3988
Share registryBOARDROOM PTY LIMITED

Dividends

Oncosil Medical does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Oncosil Medical.

NameTitleAgeTotal Pay
Mr. Karl David PechmannCFO & Company Sec.305.31k
Mr. Nigel LangeCEO, MD & Pres of EMEA
Mr. Michael WarrenerGlobal Sales & Marketing Director
Dr. David Charles JamesGlobal Head of Manufacturing Operations
Mr. Charles RowlandPres of US Operations69
Dr. Ralph PetersChief Medical Officer
Mr. David TurnerHead of Medical Affairs

Profitability and management effectiveness

Profit margin

-253.04%

Operating margin

-268.35%

Return on assets

-27.06%

Return on equity

-46.09%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Oncosil Medical is 67.01M and its enterprise value is 62.08M. The enterprise value to revenue ratio of OSL is 28.02.

The OSL's stocks Beta value is 0.15 making it 85% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Oncosil Medical (OSL)

Oncosil Medical (ASX:OSL) Frequently Asked Questions

1. What is Oncosil Medical's Stock Symbol?

Oncosil Medical trades on ASX under the ticker symbol "OSL".

2. What is Oncosil Medical's stock price today?

One share of OSL stock can currently be purchased for approximately $0.083.

3. How can I contact Oncosil Medical?

Oncosil Medical's mailing address is 15 Blue Street Suite 503 Level 5 North Sydney NSW 2060 Australia. The company can be reached via phone at 61 2 9223 3344.

4. What is Oncosil Medical's official website?

The official website of Oncosil Medical is http://www.oncosil.com.au.

5. Which share registry manages Oncosil Medical's stock?

Oncosil Medical's stock is managed by BOARDROOM PTY LIMITED.